Compare DexCom, Inc. (DXCM) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs VNET Group Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: DexCom, Inc. is far larger — about 21.7× VNET Group Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and VNET Group Inc for 16 Days on average.
| DXCM | VNET | |
|---|---|---|
Market Cap | $31.86B | $1.47B |
Volume | 3,607,070 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $92.34 | $14.03 |
52-Week Low | $54.84 | $5.13 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $31.32B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
VNET trades at $5.53, up 2.6% today but near 52-week lows. The technical picture is bearish with negative moving averages, while fundamentals show revenue growth to $9.95B in 2025 but persistent losses with a -22.18% net margin. Recent strategic investments and AI infrastructure partnerships provide growth catalysts, but balance sheet concerns and negative cash flow remain challenges.
Outlook remains cautious despite 62.5% analyst buy ratings. The stock offers speculative upside from AI data center demand and recent strategic investments, but risks include heavy debt load, negative profitability, and Chinese regulatory exposure. Investors should weigh growth potential against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
